Type 2 diabetes patients on insulin therapy now have compelling evidence that upgrading their glucose monitoring technology delivers measurable health benefits. The shift from fingerstick testing to continuous monitoring represents more than convenience—it translates to clinically meaningful improvements in blood sugar control and reduced risk of dangerous hypoglycemic episodes. This comprehensive analysis of thirteen randomized controlled trials involving 1,550 patients reveals that continuous glucose monitoring (CGM) systems outperform traditional self-monitoring of blood glucose (SMBG) in two critical areas. Patients using CGM devices achieved HbA1c reductions of 2.78 mmol/mol compared to those relying on fingerstick measurements—a difference that, while modest, represents improved long-term glucose control. More significantly, CGM users experienced 1.30% fewer episodes of time below range (TBR), indicating substantially reduced hypoglycemia risk. These findings carry particular weight given the study's rigorous methodology, analyzing only randomized controlled trials with minimum six-week durations. However, the analysis reveals important nuances that temper enthusiasm. The research showed high statistical heterogeneity, suggesting CGM benefits may vary considerably between individual patients or device types. Additionally, improvements in time-in-range and reductions in hyperglycemic episodes, while trending positive, failed to reach statistical significance. This meta-analysis confirms CGM as a valuable clinical tool for insulin-dependent type 2 diabetes patients, particularly those struggling with hypoglycemic episodes. Yet the substantial variability in outcomes suggests personalized approaches remain essential. The technology appears most beneficial for patients with frequent glucose fluctuations rather than a universal solution for all insulin users.